Drugs & 
Pill 
Drug Interaction 
Symptom 
Side 
Conditions 
Treatment 
Compare 
My Med 
Discount 
FDA 
Price 
Phonetic 
Health Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
Bavarian Nordic Receives U.S. FDA Approval of Jynneos Freeze-Dried Smallpox and Mpox Vaccine
COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Qfitlia (fitusiran) to Treat Hemophilia A or B With or Without Inhibitors
Paris, March 28, 2025. The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine...
FDA Approves Imfinzi (durvalumab) for Muscle Invasive Bladder Cancer
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment,...
FDA Approves Novartis Radioligand Therapy Pluvicto for Earlier Use Before Chemotherapy in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Basel, March 28, 2025 – Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan)...
FDA Approves Conexxence (denosumab-bnht), a Biosimilar to Prolia
Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilar Conexxence (denosumab-bnht) of its operating company Fresenius...
FDA Approves Vykat XR (diazoxide choline) to Treat Hyperphagia in Prader-Willi Syndrome
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing...
Combination Immunotherapy Shrank a Variety of Metastatic Gastrointestinal Cancers
A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness...
FDA Approves First At-Home Test to Diagnose Three STIs in Women
The U.S. Food and Drug Administration granted marketing authorization for the first home-based, nonprescription diagnostic test for chlamydia, gonorrhea,...
Common Photosensitizing Drugs Increase Skin Cancer Risk
Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology, Photoimmunology...
Similar Efficacy Seen for Isodose, Dose-Escalated MHFRT, CFRT in Prostate Cancer
For patients with prostate cancer, isodose and dose-escalated moderately hypofractionated radiotherapy (MHFRT) have similar efficacy as conventionally...
AI Model Can Optimize, Standardize Total Parenteral Nutrition Formulas
An artificial intelligence (AI) approach identified total parenteral nutrition (TPN) formulas that increase safety and potentially reduce costs for neonates...
Subclinical Cardiac Dysfunction Linked to Markers of Neurodegeneration
Subclinical cardiac dysfunction is associated with brain imaging markers of neurodegeneration, according to a study published online March 26 in Neurology. Amber...
Experts Concerned as NIH Axes Critical Vaccine Study Funds
Hundreds of U.S. research projects aimed at boosting vaccine confidence have been shut down -- just as preventable diseases like measles and flu are on...
Brain Implant Lets Woman Talk After 18 Years of Silence Due to Stroke
For nearly two decades, a stroke had left a woman unable to speak -- until now. Thanks to a new brain implant, her thoughts are being turned into...
Major Job Cuts at NIOSH Pose Risks to Worker Safety, Critics Warn
A major round of job cuts at the National Institute for Occupational Safety and Health (NIOSH) could weaken efforts to protect American workers, according...
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti for the Treatments of Acute Bipolar I Disorder and Schizophrenia
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration...
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
PRINCETON, N.J. and TOKYO, JAPAN March 31, 2025 – Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co.,...
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
(BUSINESS WIRE)--Mar. 31, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development...
FDA Issues Complete Response Letter for Etripamil for PSVT
MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S....
Sugar Substitute Appears To Boost Appetite, Hunger
Splenda doesn’t directly add calories to your diet, but the sweetener still might lead people to pack on pounds, a new study says. The sugar substitute...
Recently Added
Recently added consumer and prescribing information: Miudella, Opdivo Qvantig, Alyftrek, Crenessity, Ensacove, Steqeyma, Yesintek, Revuforj, Danziten, Aucatzyl
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex CareNotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Qfitlia Qfitlia (fitusiran) is an antithrombin-directed small interfering ribonucleic acid for the prophylactic treatment of people with hemophilia...
- Bomyntra Bomyntra (denosumab-bnht) is a RANK ligand (RANKL) inhibitor biosimilar to Xgeva (denosumab) for use in the prevention of skeletal-related...
- Conexxence Conexxence (denosumab-bnht) is a RANK ligand (RANKL) inhibitor biosimilar to Prolia (denosumab) used in the treatment of osteoporosis.
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...
Drug Information
Tools
- Interaction Checker
- Pill Identifier
- Symptom Checker
- Medication Record
- Mobile Apps
- Drug Imprint Codes
- Community Support
- Compare Drugs
News & Alerts
- Medical News
- Clinical Trial Results
- FDA Drug Alerts
- FDA Consumer Updates
- New FDA Approvals
- New Drug Applications
- Drug Shortages
- Video Center
- Popular Articles
Professionals
Top 100 Drugs
- Abilify
- Adderall
- Aimovig
- Ambien
- Atorvastatin
- Austedo
- Avastin
- Benlysta
- Biktarvy
- Botox
- Breztri
- Buprenorphine
- Cabenuva
- Cimzia
- Cosentyx
- Diazepam
- Descovy
- Diclofenac
- Doxycycline
- Duloxetine
- Dupixent
- Emgality
- Enhertu
- Entyvio
- Epclusa
- Erleada
- Evenity
- Fasenra
- Farxiga
- Gabapentin
- Gemtesa
- Humira
- Ibuprofen
- Imbruvica
- Januvia
- Jardiance
- Kesimpta
- Keytruda
- Kisqali
- Leqembi
- Leqvio
- Lexapro
- Lybalvi
- Lyrica
- Metformin
- Methadone
- Methotrexate
- Mounjaro
- Naloxone
- Naltrexone
- Nucala
- Nurtec
- Ofev
- Opdivo
- Orladeyo
- Otezla
- Oxycodone
- Ozempic
- Paxlovid
- Penicillin
- Praluent
- Prednisone
- Prozac
- Qulipta
- Quviviq
- Reblozyl
- Repatha
- Restasis
- Rexulti
- Rybelsus
- Semaglutide
- Seroquel
- Sildenafil
- Skyrizi
- Sotyktu
- Stelara
- Sublocade
- Taltz
- Tepezza
- Tramadol
- Tremfya
- Trintellix
- Tylenol
- Ubrelvy
- Vabysmo
- Venclexta
- Verzenio
- Viagra
- Vijoice
- Vraylar
- Vumerity
- Vyepti
- Vyvanse
- Vyvgart
- Wegovy
- Wellbutrin
- Xanax
- Xolair
- Xyrem
- Zepbound
